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IgG from Patients with Bullous Pemphigoid Depletes
Cultured Keratinocytes of the 180-kDa Bullous
Pemphigoid Antigen (Type XVII Collagen) and
Weakens Cell Attachment
Hiroaki Iwata1, Naoko Kamio1, Yumi Aoyama1, Yukari Yamamoto1, Yoshiaki Hirako2, Katsushi Owaribe2
and Yasuo Kitajima1
We have shown that binding of bullous pemphigoid (BP)-patient IgG (BP-IgG) causes the internalization of
BP180 from the cell membrane. This study examined whether BP-IgG treatment can deplete cultured
keratinocytes of BP180, how it affects cellular levels of a6 and b4 integrins (by western blot analysis using
monoclonal antibodies to these antigens), and whether it reduces adhesion of cells to the culture dish (by a
vibration detachment assay). All BP-IgG or BP sera with high values of BP180-ELISA from 18 BP patients before
and after oral corticosteroid treatment showed dramatically decreased BP180 in cells after 6 hours of BP-IgG
stimulation, whereas a6 and b4 integrin levels were not decreased. Even IgG from patients in whom oral
corticosteroid had suppressed active blistering could deplete cells of BP180, as long as sera retained a high
value of BP180-ELISA. On the other hand, reduction of cell BP180 content increased detachment of cells from
the dish. These results suggest that BP-IgG reduces hemidesmosomal BP180 content, weakening the adhesion
of hemidesmosomes to the lamina densa. In the presence of BP180 deficiency, inflammation generated by BP180
immune-complex formation might then tear the weakened lamina lucida, and this could lead to generation of
the BP-specific split at the lamina lucida.
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INTRODUCTION
Bullous pemphigoid (BP), which is an autoimmune blistering
skin disease, demonstrates characteristic clinical, histologic,
and immunologic features, that is, tense blisters with or
without widespread erythema, splits along the lamina lucida
beneath the basal cells at the basement zone, and the
presence of circulating autoantibodies against hemidesmo-
somal molecules, respectively (Stanley et al., 1981, 1988;
Jordon et al., 1985; Labib et al., 1986; Meyer et al., 1990).
The BP autoantibodies include two major antigens with an
apparent molecular weight of 230-kDa (Amagai et al., 1990;
Tanaka et al., 1990; Sawamura et al., 1991) and 180-kDa
(Labib et al., 1986; Meyer et al., 1990). The autoantibody
against 180-kDa BP antigen (BP180), which is a transmem-
brane collagenous protein, type XVII collagen (Diaz et al.,
1990; Green et al., 1992), is the most suspected pathogenic
agent for BP, because injection of antibody (rabbit IgG)
against the noncollagenous domain 16a of mouse BP180 into
mice has been shown to reproduce the main features of BP,
although neutrophil- but not eosinophil-dominant inflamma-
tory infiltrates were associated (Giudice et al., 1992). In
addition, most BP patients have antibodies to BP180 when
examined by western blotting using the synthetic noncolla-
genous domain 16a of BP180 as a subject (Giudice et al.,
1993, 1994; Liu et al., 1993; Matsumura et al., 1996).
However, the pathogenic roles of BP antigens in blistering
remain unclear. In this regard, we have previously shown that
BP180 is distributed in pools on the lateral-apical plasma
membrane, without being bound to keratin filaments, as well
as on the basal-plasma membrane at hemidesmosomes,
where it is bound to keratin filaments (Kitajima et al.,
1994a, b). We have also shown that the binding of BP-patient
IgG (BP-IgG) to BP180 causes the internalization of BP180
from the lateral-apical plasma membrane in cultured
keratinocytes (Kitajima et al., 1994b, 1998). This may suggest
that the internalization of BP180 plays an initial role in the
pathogenesis of BP (Kitajima et al., 1998; Kitajima et al.,
1994a, b). In this study, we examined whether the inter-
nalization of BP180 can deplete cells of BP180, whether it
affects levels of a6 and b4 integrins, which are also
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components of hemidesmosomes, and whether it reduces the
adhesion of cells to the culture dish. To determine whether
internalization of BP180 affects levels of a6 and b4 integrins,
we used semiquantitative western blot analysis with mono-
clonal antibodies to BP180, a6 integrin, b4 integrin, and
b-catenin (as an internal quantitative control).
RESULTS
BP-IgG stimulation depletes normal human keratinocytes and
DJM-1 cells of BP180
When normal human keratinocytes (NHKs) and DJM-1
keratinocytes at 40% confluence were treated with
0.5mgml1 of BP-IgG at the BP180-ELISA index value of
120 and compared with the results of normal human IgG
treatment as normalized to b-catenin, approximately 40–50%
of BP180 was already depleted from the cell at 2 hours. More
prominently, approximately 75% (in DJM-1 cells)–85% (in
NHKs) of BP180 was depleted at 6 hours. As almost the same
results were obtained using NHKs and DJM-1 cells 3.5 hours
and 6 hours after BP-IgG stimulation, most of our experiments
were performed by 6-hour stimulation with BP-IgG and BP
sera using DJM-1 cells, with the exception of a few BP cases
(Figure 1a and b). In contrast, the cellular levels of b4 and a6
integrins were not affected at any time point during BP-IgG
treatment (Figure 1a and b). Taking this into consideration,
we used b-catenin as the nonhemidesmosomal internal
standard and b4 integrin as the hemidesmosomal internal
standard and obtained the ratios of BP180 to b-catenin and to
b4 integrin to perform a semiquantitative analysis of BP180 in
cells for further experiments. Due to the small amount of sera
available from patients, and because the same results were
obtained when the complement-inactivated sera were used
instead of IgG (not shown), we performed further experiments
to compare sera from other patients with BP before/after oral
corticosteroid treatment and those from normal control
volunteers by incubating with complement-inactivated sera
for 6 hours.
Effects of oral corticoid treatment on the BP180-depleting
activity of BP patients’ sera
Most of the sera (7 of 9) with high index values of BP180-
ELISA (130–221) from BP patients before oral corticosteroid
treatment demonstrated marked BP180-depleting activity
(Figure 2, left panels). Stimulation with these sera caused an
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Figure 1. Effects of BP-IgG stimulation on cellular levels of BP180. (a) Cultured normal human keratinocytes (NHKs) and (b) DJM-1 cells. When NHKs and
DJM-1 cells at 40% confluence were treated with 0.5mgml1 of BP-IgG for 2 hours, approximately 40–50% of BP180 was already depleted from the cells
(compared to the results of normal human IgG treatment as normalized to b-catenin). After a 6-hour incubation with BP-IgG, BP180 was extensively
depleted (approximately 75–85%) from both NHKs and DJM-1 cells. In contrast, b4 and a6 integrins were basically unaffected by BP-IgG stimulation at
any time point; y axis: b4 integrin, BP180, and a6 integrin content ratios (%) to b-catenin. The index value obtained at incubation time point 0 was calculated at
100%; x axis: incubation time.
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approximately 80–95% depletion of BP180 from cells
compared to normal control sera, whereas the remaining
two (cases 3 and 8) of nine cases reduced BP180 by
only approximately 50%, when BP180 content was normal-
ized to either b-catenin or b4 integrin (Figure 2, left panels).
In contrast, sera from the same patients after oral corticoster-
oid treatment lost BP180-depleting activity as their ELISA
index values were normalized (Figure 2, right panels).
Although cases 3 and 8 reduced BP180 by only approxi-
mately 50%, their ELISA index values were as high as 183
and 149, respectively. This indicates that sera from some BP
patients with high ELISA index values do not always
demonstrate the same level of cell biological activity in
terms of BP180 depletion in the culture system, even though
these patients had clinical symptoms of blistering (Figure 2,
left panels).
Markedly different results were demonstrated in sera from
a group of BP patients whose lesions had been resolved by
oral corticosteroid treatment, even without significant de-
creases in BP180-ELISA index values (192 before and 171
after treatment on average). Most sera (7 of 9) from these BP
patients maintained the same level of BP180-depleting
activity as they had had before corticosteroid treatment
(Figure 3, compare right with left panels). It is of interest to
note that cases 1 and 6 in Figure 3 did not show any marked
BP180-depleting activity (only 59 and 12%, respectively) and
did not demonstrate marked changes in BP180-depleting
activity before and after oral corticosteroid treatment when
normalized to either b-catenin or b4 integrin, although
BP180-ELISA index values were also not altered (Figure 3,
compare right with left panels). Even after blistering was
resolved by oral corticosteroid treatment, BP180-depleting
activity was demonstrated in association with sustained index
values of BP180-ELISA (Figure 3). Using NHKs, two
representative BP sera samples and one normal serum sample
before and after corticosteroid treatment were also examined.
The results obtained were almost the same as those in the
case of DJM-1 cells (Figure 4).
BP180 content was significantly reduced compared to b4
integrin from BP patients skin
The ratio of BP180 to b4 integrin, which is another
transmembrane-peptide component of the hemidesmosome,
was reduced approximately 40% as determined by western
blot analysis using cryosections of biopsies from each of four
BP patients compared to those from normal volunteers. This
suggests that BP180 content is also reduced in the perile-
sional skin of BP patients (Figure 5).
No effects of corticosteroid on the BP180 assay system in terms
of BP-IgG BP180-depleting activity
Preincubation for 24 hours and coincubation with predniso-
lone at 0.2mgml1, which is equivalent in serum concentra-
tion to 1,000mg prednisolone IV pulse therapy, and at
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Figure 2. BP180-depleting activity of BP sera before and after oral corticosteroid treatment in patients whose BP180-ELISA index values were reduced to
normal levels after treatment. DJM-1 cells were incubated with sera for 6 hours, and total cell lysates were subjected to western blot analysis. Most sera (7 of 9)
with high index values of BP180-ELISA (130–221) from BP patients before oral corticosteroid treatment demonstrated marked BP180-depleting activity
(left panels). Stimulation (for 6 hours) with these sera caused an approximately 80–95% depletion of BP180 from cells compared to normal control sera, when
BP180 content was normalized to either b-catenin or b4 integrin. However, the remaining two sera (cases 3 and 8) reduced BP180 by only approximately 50%
(left panels). In contrast, sera from the same patients after oral corticosteroid treatment lost BP180-depleting activity as ELISA index values were normalized (right
panels); y axis, BP180 content ratios (%) to b4 integrin and b-catenin. The control index value with normal human IgG treatment was calculated at 100%; x axis:
the serum number of 9 patients (nos. 1–9) and a normal volunteer (no. 10).
www.jidonline.org 921
H Iwata et al.
Bullous Pemphigoid IgG Depletes Keratinocytes of BP180
0.01mgml1, which is equivalent in serum concentration to
60mg per day of oral prednisolone, did not exert any effects
on the BP180-depleting activity of BP-IgG (Figure 6). This
suggests that corticosteroid does not directly affect the
BP180-depleting activity of BP-IgG.
Reduction of BP180 content is associated with a decrease in
adhesion strength to the culture plate as determined by
detachment assay of colonies
Bullous pemphigoid (BP)-patient IgG (2mgml1) treatments
significantly decreased the adhesion strength of cells to the
cultured plate in both NHKs and DJM-1 cells, whereas
normal IgG treatments did not (Figure 7). Although BP-IgG
dramatically depleted cells of BP180, that is, approximately
85% in NHKs and 75% in DJM-1 cells compared with
nontreated controls (Figure 1), adhesive strength was reduced
by only approximately 40% in both NHKs and DJM-1 cells
(Figure 7), suggesting that other adhesive molecules, such as
b4 and a6 integrins, may contribute to adhesive strength.
DISCUSSION
With regard to blistering mechanisms after autoantibodies
bind to the BP180 antigen, Liu et al. (1995) compared the
effects of anti-BP180 antibodies on blistering in C5-sufficient
and C5-deficient mouse strains and suggested that comple-
ment activation by anti-BP180 antibodies is required to cause
blistering in the mouse model. Therefore, autoantibodies
against BP180 itself cannot cause skin blisters without
inflammatory enzymatic digestion caused by complement
activation. However, this does not explain why splits that
generate blisters run specifically along the intra-lamina
lucida, but not the sublamina densa or even the intercellular
adhesion of basal cells. There is no reason why proteolysis
and tissue damage due to complement-induced inflammation
should be accurately limited to the lamina lucida, which is
only 500 nm in width. In epidermolysis bullosa aquisita,
complement activation usually causes sublamina densa
blistering (Gammon and Briggaman, 1993; Sitaru et al.,
2006), although in systemic lupus erythematosus, comple-
ment activation is associated with basal-cell degeneration
and/or blistering at the sublamina densa region, but not along
the lamina lucida (Crowson and Magro, 2001).
The present results may help resolve this issue. We
demonstrated that BP-IgG/serum can deplete cells of
BP180, reducing the adhesion of cells to the bottom of the
culture plate. This suggests that hemidesmosomes have an
insufficient adhesive function due to a shortage of BP180.
The BP180 depletion may be caused by BP180 endocytosis
induced by BP180-autoantibody immune complex forma-
tion, as we have previously shown in culture and in patients’
epidermal basal cells (Matsumura et al., 1996; Kitajima et al.,
1994a, b). We can therefore reasonably speculate that
hemidesmosomes of patients’ epidermal basal cells also have
diminished adhesive strength due to a possible decrease in
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Figure 3. BP180-depleting activity of BP sera before and after oral corticosteroid treatment in patients whose BP180-ELISA index values remained basically
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were subjected to western blot analysis. Most sera (7 of 9) from BP patients with high index values of BP180-ELISA (151–242) maintained the same
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BP180 content. However, although the weakened hemides-
mosomes may be more susceptible to proteolysis than other
intact components of the dermal–epidermal junction, they
must retain some strength, as the skin does not spontaneously
blister. Thus, it appears plausible that the immune complexes
of BP-IgG and BP180 activate complement, which causes
migration of neutrophils and inflammation, leading to
dermal–epidermal separation (Liu et al., 1995). Apart from
the binding of BP-IgG to BP180, the antigen molecules,
which are already integrated into the hemidesmosome, may
not be internalized because previous studies have shown no
intracellular punctate pattern of BP230 (BPAG1) in associa-
tion with the punctate distribution of BP180 (BPAG2) in
epidermal basal cells or cultured keratinocytes (Kitajima
et al., 1994a, b). This may also suggest that BP-IgG
stimulation did not significantly reduce a6 or b4 integrins.
This was also shown in the present study, through
western blot analysis of perilesional skin from BP patients,
showing an approximately 40% reduction in the BP180/b4
integrin ratio.
Taken together, these results may suggest that BP-IgG
reduces the BP180 content of hemidesmosomes, decreasing
their adhesion to the lamina densa. Hence the inflammation
generated by BP180 immune-complex formation may tear
the weakened lamina lucida due to BP180 deficiency. In
combination with nonspecific inflammatory enzymatic activ-
ity exerted at the dermal–epidermal zone, this may cause the
BP-specific split at the lamina lucida. In this regard, it is of
great interest to note that generalized atrophic benign
epidermolysis bullosa (OMIM no. 226650)—an autosomal
recessive blistering disease characterized by blistering
dermal–epidermal separation leading to skin fragility and
atrophy, nail dystrophy, dental anomalies, and alopecia of
the scalp, eyebrows, and secondary sexual hair (Hintner and
Wolff, 1982)—is caused by mutations in collagen type XVII
a-1 (COL17A1 mapped at 10q24.3), leading to the lack of the
COL17A1 gene product (BP180) and the resultant skin
fragility (Jonkman et al 1995; Schumann et al., 1997). Thus,
if BP180 is extensively depleted from hemidesmosomes in
the skin of BP patients, who have a very high index value of
anti-BP180 antibody, this may render the skin fragile enough
to generate friction blisters. In this case, this could also
account for skin blistering in forms of BP associated with low
inflammatory infiltrates (paucicellular BP).
Once the basal cells are ruptured, BP230, an intracyto-
plasmic antigen, is exposed to immune systems to produce
anti-BP230 antibody. Because it is an intracytoplasmic
protein, BP230 may have higher antigenicity than the
extracellular BP180 antigen. Anti-BP230 antibody seems
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Figure 4. BP180-depleting activity of BP sera before and after remission of
blistering by oral corticosteroid treatment as examined using cultured
normal human keratinocytes (NHKs). NHKs were incubated with sera for
6 hours and total cell lysates were subjected to western blot analysis. BP
serum (designated A) with a reduced index value of BP180-ELISA (162–8.6)
from a BP patient (patient 1 in Figure 2) after oral corticosteroid treatment
decreased BP180-depleting activity markedly, whereas BP serum
(designated B) with a retained high index value of BP180-ELISA (136) from a
BP patient (patient 4 in Figure 3) sustained the BP180-depleting activity even
after oral corticosteroid treatment, when BP180 content was normalized to
either b-catenin or b4 integrin; y axis: BP180 content ratios (%) to b4 integrin
and b-catenin. The control index value with normal human serum
treatment was calculated at 100%; x axis: A, sera from patient 1 in Figure 2;
B, serum from patient 4 in Figure 3.
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to produce large amounts of immune complex at the
dermal–epidermal junction, as suggested by elution studies
of patient skin sections showing that most bound BP-IgG is
present as anti-BP230 (Korman, 1995). We speculate that
internalization of BP180 bound by anti-BP180 antibodies
disturbs the supply of BP180 and impairs hemidesmosomal
formation, and is thus is a primary cause of blistering in BP.
Thus far, this speculation is supported only by the present
evidence of depletion of BP180 from the cells and BP patient
skin, in addition to previous evidence of internalization of
BP180 in cultured keratinocytes and in situ in the epidermis
of BP patients (Kitajima et al., 1998; Kitajima et al., 1994a, b).
Nonetheless, this appears to be a promising line of research.
MATERIALS AND METHODS
Sera and IgGs from BP patients
In accordance with Gifu University Hospital bylaws and standard
operating procedures approved by the Gifu University Hospital
Review Board, we obtained patient consent for experimental
procedures to be performed in Gifu University Hospital from each
participating patient upon his or her first visit to the hospital. Studies
were conducted according to the Helsinki guidelines. BP-IgGs were
purified from two active BP patients, who were diagnosed with BP
based on the presence of typical clinical, histologic, and immuno-
pathologic findings in addition to the index value of BP180-ELISA,
and from normal human volunteers. BP180-ELISA index values were
determined using a BP180 NC16a ELISA kit, MESACUP BP180
(MBL, Nagoya, Japan). Briefly, each well of standard 96-well
microtiter plates was coated with recombinant glutathione
S-transferase-noncollagenous domain 16a or the same amount of
recombinant glutathione S-transferase. Sera diluted 101-, 16  101-,
or 64  101-fold were incubated in duplicate and ELISA index
values were determined in accordance with the instructions of the
manufacturer. The cutoff value was 9. Sera obtained from an
additional 16 patients with BP were used in the experiments because
of difficulties in obtaining enough sera from individual patients to
purify enough IgG. Using sera from two representative BP patients,
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we confirmed that the complement-inactivated sera exerted the
same results as IgG from BP patients, as shown in the Results section.
Antibodies
Monoclonal antibodies, mAb-233 against BP180, were produced
using a hemidesmosomal fraction from bovine corneal epithelium as
antigen. The methods for production and the characterization of the
antibodies are described elsewhere (Owaribe et al., 1991; Nishiza-
wa et al., 1993). Antibodies against a6 integrin (mouse mAb 1A10)
and b4 integrin (mouse mAb M126) were purchased from Abcam
(Tokyo, Japan), and those against b-catenin (mouse mAb 14) were
supplied by BD Biosciences (San Jose, CA).
Cell culture
DJM-1 cells isolated from human skin squamous-cell carcinoma
(Kitajima et al., 1988) were seeded either in 35-mm dishes or on
glass cover slips. Cells were cultured in Eagle’s minimum essential
medium (Nissui, Tokyo, Japan), containing 10% fetal calf serum,
0.4 mgml1 hydrocortisone (Sigma-Aldrich, St Louis, MO),
20 ngml1 epidermal growth factor (TOYOBO, Osaka, Japan),
84 ngml1 cholera toxin (List Biological Laboratories, Campbell,
CA), and 1.8mM Ca2þ (Kitajima et al., 1988). Normal human
epidermal keratinocytes from neonatal foreskin were cultured first in
EpiLife medium containing 0.06mM CaCl2 and EpiLife Defined
Growth Supplement. When used for experiments, they were cultured
in Eagle’s minimum essential medium, containing 1.8mM CaCl2 for
24 hours. They were cultured to approximately 40% confluence and
used as described below. A 40% confluence was employed because
preliminary experiments had shown that higher confluence was
less effective in BP-IgG stimulation, although it was also susceptible
to the BP180-depleting effect of BP-IgG stimulation (results not
shown).
Antibody stimulation and western blotting
To examine the effects of BP-IgG on BP180 depletion in DJM-1 cells,
BP-IgG and normal human IgG (as a negative control) were added to
final concentrations of 0.5mgml1 in the culture medium and
incubated for 30minutes, 0.5, 2, 3.5, and 6 hours. For the
experiments to examine the effects of corticosteroid on the present
assay system, prednisolone was added in the culture medium 1 and
24 hours before as well as during experiments at 0.2mgml1, which
is equivalent in serum concentration to 1,000mg prednisolone IV
pulse therapy, and at 0.01mgml1, which is equivalent in serum
concentration to 60mg per day of oral prednisolone. For western
blot analysis of whole-cell lysates, cells were lysed in 2% SDS
sample buffer (62.5mM Tris-HCl, pH 6.8, 30% glycerol, and 2% b-
mercaptoethanol) and the lysates were centrifuged at 100,000g for
1 hour after the cells were stimulated with IgG or sera. Samples were
heated at 100 1C for 5minutes. Protein concentrations were
determined spectrophotometrically using a DC Protein assay kit
(Bio-Rad, Richmond, CA). Each fraction (10 mg of protein per lane)
was subjected to reducing SDS–PAGE in 6% polyacrylamide gels
(Kitajima et al., 1992). Blots were washed with Tris-buffered saline
containing 0.05% Tween-20 and then incubated with each primary
antibody, followed by HRP-conjugated goat anti-mouse and rabbit
antibodies (DakoCytomation, Glostrup, Denmark) diluted in Tris-
buffered saline containing 0.05% Tween-20. Blots were visualized
with ECL Plus reagent (GE Healthcare Life Sciences, Amersham,
Buckinghamshire, UK). The density of the band was measured with a
Lane Analyzer (version 3.0; ATTO, Tokyo, Japan).
For quantitative western blot analysis of BP180 content in whole-
cell lysates, we first examined whether BP-IgG could also affect the
content of a6 integrin, b4 integrin, or b-catenin. None were affected,
as shown in the Results section. Therefore, BP180 levels were
normalized to b-catenin for the remaining experiments.
Semiquantitative analysis of BP180 content in BP patients’ skin
Cryosections of biopsies from each of four BP patients and three
normal volunteers were lysed in 2% SDS sample buffer (62.5mM
Tris-HCl, pH 6.8, 30% glycerol, and 2% b-mercaptoethanol) by
heating at 100 1C for 5minutes, and the lysates were centrifuged at
100,000g for 1 hour. Western blot analysis was performed by the
same methods as the analysis for cell culture experiments as
mentioned above, except for internal standard. In the case of
cryosection specimens, b4 integrin was used as an internal standard
instead of b-catenin, because b4 integrin is contained only in
hemidesmosomes in skin, whereas b-catenin is contained in other
types of skin cells such as fibroblasts and endothelial and
inflammatory cells, that may be contained in the biopsy specimens.
Detachment of colonies from the bottom of the culture plate
Cells (8 104) were seeded in 35-mm-diameter dishes and
cultured in Eagle’s minimum essential medium for 50 hours. With
this culture method, at a culture time point of 50 hours (preincuba-
tion) plus 6 hours (antibody stimulation), cells form a number of
small colonies but do not form large sheets. These cells were
stimulated with BP-IgG (2mgml1) or BP sera (20%) for 6 hours at
37 1C. The adhesion of NHKs and DJM-1 cells to the bottom of the
culture plate was assayed by determining the number of adherent
cells after vibration with a Vortex at grade 4.5 for 30minutes. Cells
retained on the bottom of the culture plate were treated with 0.25%
trypsin for 5minutes at 37 1C and released completely into the
medium by pipetting. The released cells were counted using a blood
cell counter under a microscope.
Statistics
Data are expressed as means±standard deviations from three different
measurements for individual samples from three different experiments.
Statistical significance of the observed effects was assessed with a
Student’s t-test (Po0.05 was considered significant). Statistical
analysis was done with StatMate (ATMS Co. Ltd., Tokyo, Japan).
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported by Grants-in-aid for Scientific Research from the
Ministry of Education, Culture, Sports, Science and Technology of Japan,
the Health and Labor Sciences Research Grants for Research on Measures
for Intractable Disease, and the Ministry of Health, Labor and Welfare
of Japan.
REFERENCES
Amagai M, Hashimoto T, Tajima S, Inokuchi Y, Shimizu N, Saito M et al.
(1990) Partial cDNA cloning of the 230-kD mouse bullous pemphigoid
antigen by use of a human monoclonal antibasement membrane zone
antibody. J Invest Dermatol 95:252–9
www.jidonline.org 925
H Iwata et al.
Bullous Pemphigoid IgG Depletes Keratinocytes of BP180
Crowson AN, Magro C (2001) The cutaneous pathology of lupus erythema-
tosus: a review. J Cutan Pathol 28:1–23
Diaz LA, Ratrie H III, Saunders WS, Futamura S, Squiquera HL, Anhalt GJ
et al. (1990) Isolation of a human epidermal cDNA corresponding to the
180-kD autoantigen recognized by bullous pemphigoid and herpes
gestationis sera. Immunolocalization of this protein to the hemidesmo-
some. J Clin Invest 86:1088–94
Gammon WR, Briggaman RA (1993) Epidermolysis bullosa acquisita and
bullous systemic lupus erythematosus. Diseases of autoimmunity to type
VII collagen. Dermatol Clin 11:535–47
Giudice GJ, Emery DJ, Diaz LA (1992) Cloning and primary structural analysis
of the bullous pemphigoid autoantigen BP180. J Invest Dermatol
99:243–50
Giudice GJ, Emery DJ, Zelickson BD, Anhalt GJ, Diaz LA (1993) Bullous
pemphigoid and herpes gestationis autoantibodies recognize a common
non-collagenous site on the BP180 ectodomain. J Immunol 151:5742–50
Giudice GJ, Wilske KC, Anhalt GJ, Fairley JA, Taylor AF, Emery DJ et al.
(1994) Development of an ELISA to detect anti-BP180 autoantibodies in
bullous pemphigoid and herpes gestationis. J Invest Dermatol
102:878–81
Green KJ, Virata ML, Elgart GW, Stanley JR, Parry DAD (1992) Comparative
structural analysis of desmoplakin, bullous pemphigoid antigen and
plectin: members of a new gene family involved in organization of
intermediate filaments. Int Biol Macromol 14:145–53
Hintner H, Wolff K (1982) Generalized atrophic benign epidermolysis
bullosa. Arch Dermatol 118:375–84
Jonkman MF, de Jong MC, Heeres K, Pas HH, van der Meer JB, Owaribe K
et al. (1995) 180-kD bullous pemphigoid antigen (BP180) is deficient in
generalized atrophic benign epidermolysis bullosa. J Clin Invest
95:1345–52
Jordon RE, Kawana S, Fritz KA (1985) Immunopathologic mechanisms in
pemphigus and bullous pemphigoid. J Invest Dermatol 85:72s–8s
Kitajima Y, Hirako Y, Owaribe K, Mori S, Yaoita H (1994b) Antibody-binding
to the 180-kD bullous pemphigoid antigens at the lateral cell surface
causes their internalizaiton and inhibits their assembly at the basal cell
surface in cultured keratinocytes. J Dermatol 21:838–46
Kitajima Y, Hirako Y, Owaribe K, Yaoita H (1994a) A possible cell-
biologic mechanism involved in blister formation of bullous
pemphigoid: anti-180-kD BPA antibody is an initiator. Dermatology
189(suppl 1):46–9
Kitajima Y, Inoue S, Nagao S, Nagata K, Yaoita H, Nozawa Y (1988) Biphasic
effects of 12-O-tetradecanoylphorbol-13-acetate on the cell morphology
of low calcium-grown human epidermal carcinoma cells: Involvement
of translocation and down regulation of protein kinase C. Cancer Res
98:964–70
Kitajima Y, Nojiri M, Yamada T, Hirako Y, Owaribe K (1998) Internalization
of the 180 kDa bullous pemphigoid antigen as immune complexes in
basal keratinocytes: an important early event in blister formation in
bullous pemphigoid. Br J Dermatol 138:71–6
Kitajima Y, Owaribe K, Nishizawa Y, Jokura Y, Yaoita H (1992) Phorbol ester-
and calcium-induced reorganization 180-kDa bullous pemphigoid
antigen on the ventral surface of cultured human keratinocytes as
studied by immunofluorescence and immunoelectron microscopy. Exp
Cell Res 203:17–24
Korman NJ (1995) In situ-bound antibodies eluted from the skin of patients
with bullous pemphigoid are preferentially directed against the 230-kD
bullous pemphigoid antigen. J invest Dermatol 105:824–30
Labib RS, Anhalt GJ, Patel HP, Mutasim DF, Diaz LA (1986) Molecular
heterogeneity of the bullous pemphigoid antigens as detected by
immunoblotting. J Immunol 136:1231–5
Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA et al. (1993) A passive
transfer model of the organ-specific autoimmune disease, bullous
pemphigoid, using antibodies generated against the hemidesmosomal
antigen, BP180. J Clin Invest 92:2480–8
Liu Z, Giudice GJ, Swartz SJ, Fairley LA, Till GO, Troy JL et al. (1995) The role
of complement in experimental bullous pemphigoid. J Clin Invest
95:1539–44
Matsumura K, Amagai M, Nishikawa T, Hashimoto T (1996) Majority of
bullous pemphigoid and herpes gestationis sera react with NC16a
domain of the 180 kD bullous pemphigoid antigen. Arch Dermatol Res
288:507–9
Meyer LJ, Taylor TB, Kadunce DP, Zone JJ (1990) Two groups of bullous
pemphigoid antigens are identified by affinity-purified antibodies.
J Invest Dermatol 94:611–6
Nishizawa Y, Uematsu J, Owaribe K (1993) HD4, a 180 kDa bullous
pemphigoid antigen, is a major transmembrane glycoprotein of the
hemidesmosome. J Biochem 113:493–501
Owaribe K, Nishizawa Y, Franke WW (1991) Isolation and characterization of
hemidesmosomes from bovine corneal epithelial cells. Exp Cell Res
19:2622–30
Sawamura D, Li K, Chu M-L, Uitto J (1991) Human bullous pemphigoid
antigen (BPAG1) amino acid sequenced from cloned cDNAs predict
biologically important peptide segments and protein domains. J Biol
Chem 266:17784–90
Schumann H, Hammami-Hauasli N, Pulkkinen L, Mauviel A, Ku¨ster W,
Lu¨thi U et al. (1997) Three novel homozygous point mutations and a new
polymorphism in the COL17A1 gene: relation to biological and clinical
phenotypes of junctional epidermolysis bullosa. Am J Hum Genet
60:1344–53
Sitaru C, Chiriac MT, Mihai S, Bu¨ning J, Gebert A, Ishiko A et al. (2006)
Induction of complement-fixing autoantibodies against type VII collagen
results in subepidermal blistering in mice. J Immunol 177:3461–8
Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI (1981)
Characterization of bullous pemphigoid antigen: a unique basement
membrane protein of stratified epithelia. Cell 24:897–903
Stanley JR, Tanaka T, Mueller S, Klaus-Kovtun V, Roop D (1988) Isolation of
complementary DNA for bullous pemphigoid antigen by use patient’s
auto-antibodies. J Clin Invest 82:1864–70
Tanaka T, Korman NJ, Shimizu H, Eady RAJA, Klaus-Kovtum Roop D
(1990) Production of rabbit antibodies against carboxy-terminal
epitopes encoded by bullous pemphigoid cDNA. J Invest Dermatol
94:617–23
926 Journal of Investigative Dermatology (2009), Volume 129
H Iwata et al.
Bullous Pemphigoid IgG Depletes Keratinocytes of BP180
